BridgeMD
New treatment option for Remimazolam
Official title Remimazolam Besylate in Sedation of Postcardioperative Patients
ClinicalTrials.gov ID: NCT06716840
What this study is testing
What is Remimazolam?
Remimazolam is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for remimazolam.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Intensive care medicine is vital in managing patients after cardiac surgery with endotracheal intubation，in order to provide extensive monitoring to assure clinical stabilization. During this time of recovery, sedation is frequently employed.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- age ≥ 18 years ;
- admitted to the intensive care unit after cardiac surgery with techanical ventilation；
- expected to extubation within 48hours ；
- participant has given informed consent
You likely can't join if
- pregnant or lactating women
- known or suspected hypersensitivity to the study drug
- history of impaired consciousness or psychiatric illness
- severe bradycardia with a heart rate of \< 50 beats per minute
- systolic blood pressure \< 90 mmHg with fluid resuscitation and vasopressor maintenance
- atrioventricular block（II or III degree）, Left ventricular ejection fraction(LVEF) \<30%
See the full eligibility criteria
- age ≥ 18 years ;
- admitted to the intensive care unit after cardiac surgery with techanical ventilation；
- expected to extubation within 48hours ；
- participant has given informed consent
- pregnant or lactating women
- known or suspected hypersensitivity to the study drug
- history of impaired consciousness or psychiatric illness
- severe bradycardia with a heart rate of \< 50 beats per minute
- systolic blood pressure \< 90 mmHg with fluid resuscitation and vasopressor maintenance
- atrioventricular block（II or III degree）, Left ventricular ejection fraction(LVEF) \<30%
- participated in other clinical studies within 3 months
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.